You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Naproxen Sodium And Pseudoephedrine Hydrochloride, and what generic alternatives are available?

Naproxen Sodium And Pseudoephedrine Hydrochloride is a drug marketed by Aurobindo Pharma, Dr Reddys Labs Inc, and Perrigo. and is included in three NDAs.

The generic ingredient in NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Naproxen Sodium And Pseudoephedrine Hydrochloride

A generic version of NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE was approved as naproxen sodium; pseudoephedrine hydrochloride by PERRIGO on March 17th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE?
  • What are the global sales for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE?
  • What is Average Wholesale Price for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE?
Summary for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
Drug patent expirations by year for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
Recent Clinical Trials for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dr. Reddy's Laboratories LimitedPhase 1

See all NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE clinical trials

Pharmacology for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents and Regulatory Information for NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE naproxen sodium; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 211360-001 Jun 1, 2022 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys Labs Inc NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE naproxen sodium; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 077381-001 Sep 27, 2006 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Perrigo NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE naproxen sodium; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 076518-001 Mar 17, 2004 OTC No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.